1. Home
  2. ATYR vs MBI Comparison

ATYR vs MBI Comparison

Compare ATYR & MBI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ATYR
  • MBI
  • Stock Information
  • Founded
  • ATYR 2005
  • MBI 1973
  • Country
  • ATYR United States
  • MBI United States
  • Employees
  • ATYR N/A
  • MBI N/A
  • Industry
  • ATYR Biotechnology: Biological Products (No Diagnostic Substances)
  • MBI Property-Casualty Insurers
  • Sector
  • ATYR Health Care
  • MBI Finance
  • Exchange
  • ATYR Nasdaq
  • MBI Nasdaq
  • Market Cap
  • ATYR 330.7M
  • MBI 311.3M
  • IPO Year
  • ATYR 2015
  • MBI 1987
  • Fundamental
  • Price
  • ATYR $3.97
  • MBI $5.41
  • Analyst Decision
  • ATYR Strong Buy
  • MBI Buy
  • Analyst Count
  • ATYR 6
  • MBI 2
  • Target Price
  • ATYR $18.60
  • MBI $6.75
  • AVG Volume (30 Days)
  • ATYR 2.0M
  • MBI 452.6K
  • Earning Date
  • ATYR 03-13-2025
  • MBI 05-08-2025
  • Dividend Yield
  • ATYR N/A
  • MBI N/A
  • EPS Growth
  • ATYR N/A
  • MBI N/A
  • EPS
  • ATYR N/A
  • MBI N/A
  • Revenue
  • ATYR $235,000.00
  • MBI $27,000,000.00
  • Revenue This Year
  • ATYR $1,387.23
  • MBI N/A
  • Revenue Next Year
  • ATYR $873.22
  • MBI N/A
  • P/E Ratio
  • ATYR N/A
  • MBI N/A
  • Revenue Growth
  • ATYR N/A
  • MBI 285.71
  • 52 Week Low
  • ATYR $1.42
  • MBI $3.22
  • 52 Week High
  • ATYR $4.66
  • MBI $7.46
  • Technical
  • Relative Strength Index (RSI)
  • ATYR 56.81
  • MBI 37.63
  • Support Level
  • ATYR $2.98
  • MBI $4.93
  • Resistance Level
  • ATYR $3.73
  • MBI $5.67
  • Average True Range (ATR)
  • ATYR 0.40
  • MBI 0.42
  • MACD
  • ATYR 0.04
  • MBI -0.11
  • Stochastic Oscillator
  • ATYR 80.32
  • MBI 20.08

About ATYR aTyr Pharma Inc. Common Stock

aTyr Pharma Inc is a biotherapeutics company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform. The company has concentrated its research and development efforts on a newly discovered area of biology, the extracellular functionality and signaling pathways of tRNA synthetases. Its primary focus is efzofitimod, a clinical-stage product candidate which targets NRP2 to resolve chronic inflammation that can lead to fibrosis. Efzofitimod has a novel mechanism of action for potentially treating lung inflammation and fibrosis.

About MBI MBIA Inc.

MBIA Inc provides financial guaranty insurance for municipal bonds and asset-backed securities in the United States and internationally. It offers an unconditional guarantee to repay the principal and interest on these securities if the issuer defaults. MBIA insures bonds sold in the primary and secondary markets, as well as those held in unit investment trusts and by mutual funds. It operates in three segments: the United States public finance insurance, corporate, and international & structured finance insurance. U.S. public finance insurance portfolio is managed through National Public Finance Guarantee Corporation. International & structured finance insurance business is managed through MBIA Insurance Corporation and its subsidiary.

Share on Social Networks: